BLOG IN PROGRESS - TO BE PUBLISHED BY 30 JANUARY 2025
A roundup of developments that could change diabetes management this year.We’re looking at the key players in the diabetes medtech sector.
Abbott (FreeStyle Libre)
Could a CKM spell the end for ketone urine tests?
It’s been a few years since first announced, but a new device capable of measuring both blood sugar and ketones is on the verge of becoming a reality with Abbott’s continuous ketone monitor (CKM). The device is expected to be mirror, or be similar to, the form of a FreeStyle Libre 3 sensor and it will provide real-time alerts for rising ketone levels, helping to prevent diabetic ketoacidosis (DKA).
A CKM could also enable those with type 1 diabetes to safely use SGLT inhibitors—medications like Jardiance, Farxiga, and Zynquista. This could open the door for FDA approval of these treatments for type 1 diabetes, unlocking new possibilities for care and improving overall safety.
According to Abbott, there is a pressing need for a continuous glucose-ketone monitor for individuals who are at higher risk of developing ketoacidosis and this will be the first-of-its-kind for dual monitoring.
Currently, monitoring of ketones by those with diabetes is intermittent and often only when suffering from illness, an infection is suspected or symptoms of DKA become evident. With continuous monitoring, rising ketone levels can be detected early.
Abbott are known to have been developing this medtech since at least 2022, with trials in 2023 and they already have breakthrough approval for the device from the FDA in the US. So, could this spell the end for ketone urine tests in 2025?
Reference: Abbott press release 17 June 2022. Click here.
Abbott & Medtronic (as partners)
image
Medtronic and Abbott have joined forces to develop an integrated continuous glucose monitor (CGM). Under this partnership, Abbott will provide Medtronic with a CGM designed to work exclusively with Medtronic's smart dosing devices and software, including both automated insulin delivery (AID) systems and Smart MDI setups.
This collaboration could be a game-changer, addressing one of the main reasons many people avoided Medtronic pumps in the past—the design and form factor of their sensors. Development of this new system is already underway.
Dexcom
Dexcom G7 - 15 day sensor
Dexcom has already submitted an application to the FDA for a 15-day sensor for the G7 CGM and it’s hoped approval will come in 2025. Currently, the G7 offers a wear time of 10.5 days, so this upgrade would extend monitoring by an additional five days and reduce the number of sensors needed each month from three to just two.
Approval is anticipated based on the fact that Dexcom's over-the-counter CGM, Stelo - for people with type 2 diabetes not using insulin—has already been approved as a 15-day sensor. Of course, the G7 competes with Abbott’s FreeStyle Libre products with the Libre 2 Plus already having a 15-day wear period.
Dexcom G6
In the US Dexcom have announced that the G6 is being discontinued.
Dexcom state that "G6 users on AID systems will continue to have access to Dexcom G6 until Dexcom G7 pump integrations become fully available".
Information from Dexcom about the discontinuation of G6 in the US is available here.
Eversense
The Eversense 365 implantable CGM can be worn for up to 365 days and received approval in 2024 with an iCGM designation. This makes it possible to integrate with a pump and become part of a hybrid closed loop / automated insulin delivery (AID) system.
It’s known that Eversense are already in discussions with several pump manufacturers, and a partnership announcement is anticipated in 2025.
Medtronic
In Europe, Medtronic's MiniMed 780G System with Simplera Sync, all-in-one sensor was approved and launched in 2020. It is now Europe's most utilised automated insulin delivery (AID) system.
The Simplera system has only recently been rolled out in the UK and whilst the Simplera received FDA approval in July 2024, Simplera Sync has yet to receive approval by the FDA for use in the US.
loren ipsum
Twiist
loren
loren ipsum
Tidepool
Tidepool have already agreed a partnership with Abbott for the FreeStyle Libre to be integrated.
loren ipsum
loren ipsum
Ypsomed
image
Ypsomed is a Swiss market leader in diabetes care. The company is known for, mylife Diabetes care, which includes the mylife YpsoPump insulin pump.
loren ipsum
Disclaimer
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️Love My Libre Ltd.
Love My Libre is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our website www.lovemylibre.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses the FreeStyle Libre 2 which is provided on NHS prescription.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.